Drug Trial Radar · NCT02859727
Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI
Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
37
Actual
Start
Sep 8, 2016
Primary completion
Jan 30, 2025
Study completion Jan 30, 2025
Sponsor
- Lead sponsor
- Pharming Technologies B.V.Industry
- Sponsor type
- Industry
- First posted
- Aug 9, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to provide long-term CDZ173 treatment, a selective PI3Kδ inhibitor, to the patients with genetically activated PI3Kδ, i.e., patients with APDS/PASLI who participated in the CCDZ173X2201 study or who were treated previously with PI3Kδ inhibitors other than CDZ173. The study is open-label designed to establish the long-term safety, tolerability, efficay and pharmacokinetics of CDZ173 in the target population.
Conditions
- Activated PI3Kdelta Syndrome (APDS); PASLI Disease
Interventions
CDZ173Drug
140 mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- To Evaluate the Number of Participants With (S)AEs During Treatment With CDZ173Time frame: 6 years 3 months
Locations
8 sites in 7 countries. Site status is shown where the registry gives one.
Pharming Investigative Site
Bethesda, Maryland
Pharming Investigative Site
Minsk, Belarus
Pharming Investigative Site
Prague, CZE, Czechia
Pharming Investigative Site
Dresden, Germany
Pharming Investigative Site
Brescia, BS, Italy
Pharming Investigative Site
Palermo, PA, Italy
Pharming Investigative Site
Rotterdam, Netherlands
Pharming Investigative Site
Moscow, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.